Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.21 USD
Change Today +0.55 / 1.85%
Volume 108.3K
GHDX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

genomic health inc (GHDX) Key Developments

Genomic Health Announces New Clinical Practice Study Results of the Oncotype Dx® Breast Cancer Test for Patients, Physicians and the Health-Care System

Genomic Health announced the presentation of 11 studies with the Oncotype DX® breast cancer test at the 14th St.Gallen Breast Cancer Conference [1] in Vienna, Austria. Studies presented include results from a real-life observational study in Ireland1 demonstrating significant reductions in chemotherapy and resulting cost savings when the test is used in early stage breast cancer. The study included 633 patients and was conducted to analyse both the clinical and budget impact of the test on adjuvant treatment decisions in the first 18 months since reimbursement, using real-world data from all comprehensive cancer centers across Ireland. From the 583 patients with node negative disease who were included in the analysis, the results found that 345 patients (59%) underwent a change in their treatment decision. Based on Oncotype DX Recurrence Score® results, 339 patients who were likely to derive minimal or no benefit from chemotherapy but would have been recommended this form of treatment prior to testing were changed to hormone therapy alone while six patients, who would otherwise not have been recommended chemotherapy in the absence of testing, were advised to receive it following testing. Overall, the study found that use of the Oncotype DX test led to a 58% net reduction in chemotherapy use, and net cost savings of around 800,000 from the perspective of the national public payer. The Oncotype DX breast cancer test is the only genomic test validated for its ability to predict the likelihood of chemotherapy benefit as well as risk of recurrence in early-stage breast cancer. Healthcare systems across Europe are recognising the value of the test, which is incorporated in all major international clinical guidelines. Most recently, the National Health Service (NHS) in England agreed to an access program for the Oncotype DX breast cancer test beginning April 1, 2015. The access program allows NHS hospitals to implement the National Institute for Health and Care Excellence's (NICE) guidance2, which recommends only the Oncotype DX breast cancer test for assisting in chemotherapy treatment decisions for patients with certain types of early breast cancer. In addition to England and Ireland, the Oncotype DX breast cancer test is covered in Switzerland through the mandatory health insurance system for all eligible patients as of January 1, 2015 and is reimbursed by the public insurance system in half of the regions of Spain.

Genomic Health Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Half and Full Year Ending December 31, 2015

Genomic Health Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company's total revenues were $69,126,000 against $68,819,000 a year ago. Loss from operations was $5,987,000 against $8,496,000 a year ago. Loss before income taxes was $6,166,000 against $9,247,000 a year ago. Net loss was $6,267,000 or $0.20 basic and diluted per share against $9,369,000 or $0.30 basic and diluted per share a year ago. For the year, the company's total revenues were $275,706,000 against $261,595,000 a year ago. Loss from operations was $23,627,000 against $11,832,000 a year ago. Loss before income taxes was $24,199,000 against $12,411,000 a year ago. Net loss was $24,592,000 or $0.78 basic and diluted per share against income of $12,757,000 or $0.42 diluted per share a year ago. The increased loss in 2014 was a result of planned investments in U.S. prostate commercial expansion, international market access and liquid biopsy pipeline. The company provided earnings guidance for the full-year ending December 31, 2015. The company expects total revenue of $292 million to $305 million, net loss between $17 million and $24 million, or basic net loss per share of between $0.53 and $0.75. The company expects net loss in the first half of the year to be within the full year loss guidance of $17 million to $24 million.

Genomic Health Inc. Announces Availability of Oncotype DX® Test

Genomic Health Inc. announced that, as of April 1, 2015, the Oncotype DX® test will be available to eligible breast cancer patients through the National Health Service (NHS) in England as the only multi-gene breast cancer test recommended by the National Institute for Health and Care Excellence (NICE) for use as an option to assist in chemotherapy treatment decision-making. The access program enables NHS hospitals to provide genomic testing to some of their patients by implementing the NICE final guidance, which recommends Oncotype DX as the only breast cancer test for use as an option to assist treatment decision-making in patients with early-stage, hormone receptor-positive, HER2 negative, invasive breast cancer.

Genomic Health Inc. to Report Q4, 2014 Results on Feb 10, 2015

Genomic Health Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 10, 2015

Genomic Health Inc., Q4 2014 Earnings Call, Feb 10, 2015

Genomic Health Inc., Q4 2014 Earnings Call, Feb 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GHDX:US $30.21 USD +0.55

GHDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $20.85 USD -0.66
Enzo Biochem Inc $2.88 USD -0.12
Foundation Medicine Inc $47.97 USD -0.09
NanoString Technologies Inc $10.63 USD +0.11
NeoGenomics Inc $4.72 USD 0.00
View Industry Companies
 

Industry Analysis

GHDX

Industry Average

Valuation GHDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.5x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOMIC HEALTH INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.